{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:01:43Z","timestamp":1779300103640,"version":"3.51.4"},"reference-count":25,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Associazione Italiana per la Ricerca sul Cancro","award":["MFAG 2020 ID 24698"],"award-info":[{"award-number":["MFAG 2020 ID 24698"]}]},{"name":"the Italian Ministry of Health\u20145 \u00d7 1000 funds 2017","award":["MFAG 2020 ID 24698"],"award-info":[{"award-number":["MFAG 2020 ID 24698"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Several myths and misconceptions exist about hormones in women with familial predisposition to cancer, and there are few real-life data on their prescription and uptake. To better understand how they are prescribed and accepted in healthy carriers of a BRCA1\/2 pathogenetic variant, an online survey was uploaded on Google Forms and shared through social media closed groups of patients\u2019 associations, aBRCAcadabra and ACTO Campania. A total of 241 questionnaires were collected. Sexual quality of life was considered of the utmost importance by most of the respondents (mean score of 7 \u00b1 2.8\/10), but they felt the counseling they received by healthcare professionals on the topic was insufficient (4.9 \u00b1 3.2\/10). Only 57 women out of 233 (24.5%) had used hormonal contraception after being diagnosed as carriers of a BRCA pathogenetic variant, and 42 out of 148 (28.4%) underwent menopause hormonal therapy. The majority of women (53.6% for contraception and 61.5% for menopause) reported being dissatisfied with the counseling received, and 58.2% were not aware of the protective effect of hormonal contraception on the risk of ovarian cancer. An educational effort is desirable to guarantee healthy BRCA carriers reliable contraception and evidence-based menopause counseling.<\/jats:p>","DOI":"10.3390\/cancers14143457","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T21:00:28Z","timestamp":1658091628000},"page":"3457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1\/2 Genes Pathogenic Variants: Results from an Italian Survey"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-2786","authenticated-orcid":false,"given":"Claudia","family":"Massarotti","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), School of Medicine, University of Genova, 16126 Genova, Italy"},{"name":"Academic Unit of Obstetrics and Gynaecology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Buonomo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Dellino","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, \u201cSan Paolo\u201d Hospital, ASL Bari, 70123 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Campanella","sequence":"additional","affiliation":[{"name":"aBRCAdabra, National Patient Advocacy Association for Carriers of BRCA Genes Mutation, 20019 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristofaro","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, \u201cSan Giuseppe Moscati\u201d Hospital, 83100 Avellino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-3787","authenticated-orcid":false,"given":"Alberta","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, General Surgery 3\u2014Breast Surgery, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-2626","authenticated-orcid":false,"given":"Paola","family":"Anserini","sequence":"additional","affiliation":[{"name":"Physiopathology of Human Reproduction Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, 16132 Genova, Italy"},{"name":"Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-8740","authenticated-orcid":false,"given":"Fedro A.","family":"Peccatori","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Cardoso","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","volume":"22","author":"Aguirre","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(2017). Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet. Gynecol., 130, e110\u2013e126.","DOI":"10.1097\/AOG.0000000000002296"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Buonomo, B., Massarotti, C., Dellino, M., Anserini, P., Ferrari, A., Campanella, M., Magnotti, M., De Stefano, C., Peccatori, F.A., and Lambertini, M. (2021). Reproductive issues in carriers of germline pathogenic variants in the BRCA1\/2 genes: An expert meeting. BMC Med., 19.","DOI":"10.1186\/s12916-021-02081-7"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14740338.2020.1791818","article-title":"Postmenopausal hormone therapy in BRCA gene mutation carriers: To whom and which?","volume":"19","author":"Grandi","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/13697137.2018.1514006","article-title":"Gynecological\u2013endocrinological aspects in women carriers of BRCA1\/2 gene mutations","volume":"21","author":"Doren","year":"2018","journal-title":"Climacteric"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","article-title":"Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: A systematic review","volume":"301","author":"Huber","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber, L., Davies, M., Anderson, R., Bartlett, J., Braat, D., Cartwright, B., Cifkova, R., de Muinck Keizer-Schrama, S., and Hogervorst, E. (2016). ESHRE Guideline: Management of women with premature ovarian insufficiency. Hum. Reprod., 31, 926\u2013937.","DOI":"10.1093\/humrep\/dew027"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: A population-based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"508.e1","DOI":"10.1016\/j.ajog.2021.06.070","article-title":"Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations","volume":"225","author":"Smith","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","article-title":"Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: A systematic review","volume":"147","author":"Huber","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/aogs.13120","article-title":"Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy","volume":"96","author":"Johansen","year":"2017","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13625187.2020.1849617","article-title":"What are the mechanisms of action of the different contraceptive methods to reduce the risk of ovarian cancer?","volume":"26","year":"2021","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_20","first-page":"395","article-title":"Recommendations on menopausal hormone replacement therapy","volume":"71","author":"Cagnacci","year":"2019","journal-title":"Minerva Ginecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/gme.0b013e31821606c5","article-title":"Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: Systematic review and meta-analysis","volume":"18","author":"Somboonporn","year":"2011","journal-title":"Menopause"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","article-title":"Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)","volume":"174","author":"Henry","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","unstructured":"European Parliamentary Forum for Sexual & Reproductive Rights (EPF) (2021, November 15). European Contraception Policy Atlas. Available online: https:\/\/www.epfweb.org\/node\/669."},{"key":"ref_25","unstructured":"Istituto Superiore di Sanit\u00e0 (ISS) (2022, July 08). Terapia Ormonale Post-Menopausale e Informazione alle Donne: Risultato di un Percorso di Ricerca. Available online: https:\/\/www.epicentro.iss.it\/focus\/ormoni\/ConMe2011."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:51:38Z","timestamp":1760140298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":25,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143457"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143457","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}